繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
Medtronic | 8-K: Current report
Medtronic | 8-K: Current report
美敦力 | 8-K：重大事件
牛牛AI助理已提取核心訊息
Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
美敦力報告稱2025財年第一季度營業收入爲79億，報告增長2.8%，有機增長5.3%。根據美國通用會計準則（GAAP）攤薄後每股收益上升36%，達到0.80美元，而非GAAP攤薄後每股收益增長3%，達到1.23美元。增長得益於多個業務領域的強勁表現，包括心臟消融解決方案、神經調節、脊柱、結構性心臟和糖尿病。心血管產品組合引領增長，有機增長6.9%，神經科學增長5.3%，糖尿病增長12.6%。值得注意的產品創新包括PulseSelect脈衝場消融系統、Evolut FX+經導管主動脈瓣置換（TAVR）系統和MiniMed 780G自動胰島素輸送系統。美國糖尿病業務部門表現尤其強勁，增長中段達到兩...展開全部
美敦力報告稱2025財年第一季度營業收入爲79億，報告增長2.8%，有機增長5.3%。根據美國通用會計準則（GAAP）攤薄後每股收益上升36%，達到0.80美元，而非GAAP攤薄後每股收益增長3%，達到1.23美元。增長得益於多個業務領域的強勁表現，包括心臟消融解決方案、神經調節、脊柱、結構性心臟和糖尿病。心血管產品組合引領增長，有機增長6.9%，神經科學增長5.3%，糖尿病增長12.6%。值得注意的產品創新包括PulseSelect脈衝場消融系統、Evolut FX+經導管主動脈瓣置換（TAVR）系統和MiniMed 780G自動胰島素輸送系統。美國糖尿病業務部門表現尤其強勁，增長中段達到兩位數。基於強勁的第一季度表現，美敦力提升了2025財年指導，預計有機營業收入增長爲4.5%-5%（從4%-5%上調）和非GAAP攤薄後每股收益爲5.42美元-5.50美元（之前爲5.40美元-5.50美元）。公司預計將從新產品的推出中持續增長，同時繼續進行戰略投資以支持產品發佈。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間